Build next gen medicines with Next Gen Editing

Next Gen Editing provides gene editing, computational biology, and due diligence services to biotech, pharma, and venture capital companies to help build the next generation of medicines.

The company's principal consultant, Andrew Kernytsky, established the on- and off-target gene editing platform for the world's first company-sponsored CRISPR clinical trial, exa-cel, while leading genomics and computational biology work at CRISPR Therapeutics.

Drosophila Wing Cells: CBFA2T3-GLIS2 fusion protein (red), nuclei (green), and actin filaments (purple).

Suresh Marada, National Cancer Institute / St. Jude Children's Hospital

Expertise areas

Mitigating Off-target Editing

Bringing drugs from inception to the clinic is our specialty. We design and execute successful off-target analysis for all types of therapeutics.

On-target Editing Analysis

We can help edit DNA, insert large payloads, and accurately quantify and improve the effectiveness of these changes.

Next Generation Sequencing

Since DNA sequencing was revolutionized by Next Gen Sequencing, we've been working on the algorithms behind it. Heck, we even made it the company name!

Regulatory Strategy

FDA. EMA. MHRA. Hooray! Getting regulators to understand your DNA editing strategy and approve your therapy is what we're all about.

Computational Biology

Computers and biology are our bread and butter. Peanut butter and jelly. You get the idea - we do all sorts of other analyses: epigenetics, gene expression, single cell analysis.